Avacopan — Dosing in CKD & Dialysis

Avacopan (Complement 5a Receptor (C5aR) Antagonist): renal dosing adjustments, dialyzability (Not studied in the label (no dialysis statement); plasma protein binding greater than 99.9% (Tavneos label 12.3). Level estimated from molecule size or protein binding; not measured.), and renal-relevant sa

Reviewed by Matt · November 16, 2026

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.